Published in Medical Device Business Week, October 10th, 2007
The clearance follows the successful completion of a rigorous clinical study involving 124 patients, which demonstrated dramatic plaque reduction in leg arteries with lasting results. The OASIS trial exceeded the FDA's Objective Performance Criteria (OPC) on multiple key...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week